DOT1L and leukemia: Despite the necessary improvements required to ameliorate for DOT1L-targeting molecules to improve their overall safety profile, the aforementioned results indicate that DOT1L oncogenic potential lays beyond leukemia and embraces a number of solid cancers that potentially could benefit from DOT1L pharmacological inhibition.